
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Access to a financial planner
Repare Therapeutics is a biotechnology business based in the US. Repare Therapeutics shares (RPTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.19 – an increase of 3.48% over the previous week. Repare Therapeutics employs 179 staff and has a trailing 12-month revenue of around $66.5 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Latest market close | $1.19 |
---|---|
52-week range | $1.10 - $8.49 |
50-day moving average | $2.04 |
200-day moving average | $3.06 |
Wall St. target price | $7.00 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-1.99 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.22 from 2025-02-03
1 week (2025-01-28) | 6.09% |
---|---|
1 month (2025-01-03) | -12.23% |
3 months (2024-11-05) | -68.72% |
6 months (2024-08-05) | -60.90% |
1 year (2024-02-02) | -83.10% |
---|---|
2 years (2023-02-03) | -90.13% |
3 years (2022-02-04) | 14.6 |
5 years (2020-02-01) | N/A |
Revenue TTM | $66.5 million |
---|---|
Gross profit TTM | $-57,798,000 |
Return on assets TTM | -23.39% |
Return on equity TTM | -41.17% |
Profit margin | -126.34% |
Book value | $4.12 |
Market Capitalization | $50.6 million |
TTM: trailing 12 months
We're not expecting Repare Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Repare Therapeutics's shares have ranged in value from as little as $1.1 up to $8.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Repare Therapeutics's is 0.713. This would suggest that Repare Therapeutics's shares are less volatile than average (for this exchange).
Repare Therapeutics Inc. , a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase I/Ib clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Check out the best-performing ETFs so far in 2025.